Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
Histologically, bladder cancer is a heterogeneous group comprising urothelial carcinoma (UC), squamous cell carcinoma, adenocarcinomas (ACs), urachal carcinomas (UrCs), and small cell neuroendocrine carcinomas (SCCs). However, all bladder cancers have been treated so far uniformly, and targeted ther...
Guardado en:
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a764770f5cd8462992a6a09243ba1240 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:a764770f5cd8462992a6a09243ba1240 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:a764770f5cd8462992a6a09243ba12402021-11-11T17:01:15ZEvaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer10.3390/ijms2221115471422-00671661-6596https://doaj.org/article/a764770f5cd8462992a6a09243ba12402021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11547https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Histologically, bladder cancer is a heterogeneous group comprising urothelial carcinoma (UC), squamous cell carcinoma, adenocarcinomas (ACs), urachal carcinomas (UrCs), and small cell neuroendocrine carcinomas (SCCs). However, all bladder cancers have been treated so far uniformly, and targeted therapy options are still limited. Thus, we aimed to determine the protein expression/molecular status of commonly used cancer targets (programmed cell death 1 ligand 1 (PD-L1), mismatch repair (MMR), androgen and estrogen receptors (AR/ER), Nectin-4, tumor-associated calcium signal transducer 2 (Tacstd2, Trop-2), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and fibroblast growth factor receptor 3 (FGFR3)) to give first insights into whether patients with SCC, AC/UrCs, and squamous-differentiated carcinomas (Sq-BLCA) of the bladder could be eligible for targeted therapies. In addition, for MMR-deficient tumors, microsatellite instability was analyzed. We completed our own data with molecular data from The Cancer Genome Atlas (TCGA). We present ratios for each drug and cumulative ratios for multiple therapeutic options for each nonurothelial subtype. For example, 58.9% of SCC patients, 33.5% of AC/UrCs patients, and 79.3% of Sq-BLCA patients would be eligible for at least one of the analyzed targets. In conclusion, our findings hold promise for targeted therapeutic approaches in selected patients in the future, as various drugs could be applied according to the biomarker status.Sophie WucherpfennigMichael RoseAngela MaurerMaria Angela CassataroLancelot SeillierRonja MorschEhab HammadPhilipp Heinrich BaldiaThorsten H. EckeThomas-Alexander VögeliRuth KnüchelNadine T. GaisaMDPI AGarticlebladder cancertherapeutic targetsquamous-differentiated carcinomaadenocarcinomaurachal carcinomasmall cell neuroendocrine carcinomaBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11547, p 11547 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
bladder cancer therapeutic target squamous-differentiated carcinoma adenocarcinoma urachal carcinoma small cell neuroendocrine carcinoma Biology (General) QH301-705.5 Chemistry QD1-999 |
spellingShingle |
bladder cancer therapeutic target squamous-differentiated carcinoma adenocarcinoma urachal carcinoma small cell neuroendocrine carcinoma Biology (General) QH301-705.5 Chemistry QD1-999 Sophie Wucherpfennig Michael Rose Angela Maurer Maria Angela Cassataro Lancelot Seillier Ronja Morsch Ehab Hammad Philipp Heinrich Baldia Thorsten H. Ecke Thomas-Alexander Vögeli Ruth Knüchel Nadine T. Gaisa Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer |
description |
Histologically, bladder cancer is a heterogeneous group comprising urothelial carcinoma (UC), squamous cell carcinoma, adenocarcinomas (ACs), urachal carcinomas (UrCs), and small cell neuroendocrine carcinomas (SCCs). However, all bladder cancers have been treated so far uniformly, and targeted therapy options are still limited. Thus, we aimed to determine the protein expression/molecular status of commonly used cancer targets (programmed cell death 1 ligand 1 (PD-L1), mismatch repair (MMR), androgen and estrogen receptors (AR/ER), Nectin-4, tumor-associated calcium signal transducer 2 (Tacstd2, Trop-2), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and fibroblast growth factor receptor 3 (FGFR3)) to give first insights into whether patients with SCC, AC/UrCs, and squamous-differentiated carcinomas (Sq-BLCA) of the bladder could be eligible for targeted therapies. In addition, for MMR-deficient tumors, microsatellite instability was analyzed. We completed our own data with molecular data from The Cancer Genome Atlas (TCGA). We present ratios for each drug and cumulative ratios for multiple therapeutic options for each nonurothelial subtype. For example, 58.9% of SCC patients, 33.5% of AC/UrCs patients, and 79.3% of Sq-BLCA patients would be eligible for at least one of the analyzed targets. In conclusion, our findings hold promise for targeted therapeutic approaches in selected patients in the future, as various drugs could be applied according to the biomarker status. |
format |
article |
author |
Sophie Wucherpfennig Michael Rose Angela Maurer Maria Angela Cassataro Lancelot Seillier Ronja Morsch Ehab Hammad Philipp Heinrich Baldia Thorsten H. Ecke Thomas-Alexander Vögeli Ruth Knüchel Nadine T. Gaisa |
author_facet |
Sophie Wucherpfennig Michael Rose Angela Maurer Maria Angela Cassataro Lancelot Seillier Ronja Morsch Ehab Hammad Philipp Heinrich Baldia Thorsten H. Ecke Thomas-Alexander Vögeli Ruth Knüchel Nadine T. Gaisa |
author_sort |
Sophie Wucherpfennig |
title |
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer |
title_short |
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer |
title_full |
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer |
title_fullStr |
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer |
title_full_unstemmed |
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer |
title_sort |
evaluation of therapeutic targets in histological subtypes of bladder cancer |
publisher |
MDPI AG |
publishDate |
2021 |
url |
https://doaj.org/article/a764770f5cd8462992a6a09243ba1240 |
work_keys_str_mv |
AT sophiewucherpfennig evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT michaelrose evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT angelamaurer evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT mariaangelacassataro evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT lancelotseillier evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT ronjamorsch evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT ehabhammad evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT philippheinrichbaldia evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT thorstenhecke evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT thomasalexandervogeli evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT ruthknuchel evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer AT nadinetgaisa evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer |
_version_ |
1718432194979954688 |